ArticleJournal of hand surgery global online2026
Efficacy of Splinting in Managing Adult Trigger Finger: A Systematic Review of Short-Term Outcomes.
Article in Journal of hand surgery global online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Short-Term Effects of Capacitive and Resistive Electric Transfer Therapy and Static Splinting in the Management of Trigger Finger: A Non-Randomized Clinical Study.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Trigger finger is a common hand condition often managed conservatively with splinting, which reduces pain and improves function by immobilizing the affected digit. Splinting is a viable alternative for patients wishing to avoid corticosteroid injections or surgery. Short-term studies suggest it effectively relieves symptoms; however, adherence can be challenging. This systematic review evaluates the short-term efficacy of splinting for trigger finger and aims to identify the most effective splint. Methods: A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines and registered with the International Prospective Register of Systematic Reviews Registry. Six medical databases were queried, and studies screened using predetermined inclusion criteria. Relevant data were extracted and analyzed. Results: Thirteen studies met criteria, investigating various blocking orthoses worn for 6 to 12 weeks. Splinting consistently reduced pain, stopped triggering, and improved function over the short term (within 1 year), with success rates up to 97%, comparable to corticosteroid injections but without risks like skin atrophy or infection. Regardless of splint type, splinting was most effective when worn 24 hours a day. Although the metacarpophalangeal joint blocking orthoses was the most studied orthotic, the proximal interphalangeal joint blocking orthoses (PIP-BO) outperformed the metacarpophalangeal joint blocking orthoses , providing more effective pain reduction and better functional outcome. Patients found the PIP-BO to be more comfortable and aesthetic, leading to greater wear time. Conclusions: Splinting is an effective short-term conservative treatment for trigger finger, offering symptom relief and functional improvement. Although adherence may be challenging for some patients, splinting remains a valuable option for those seeking noninvasive management. PIP-BOs superior functional outcomes, patient satisfaction, and cost-effectiveness, leads our study to recommend a PIP-BO worn continuously for at least 6 weeks, if splinting is chosen as a first-line treatment. Further research is needed to explore long-term outcomes and standardize splinting approaches for broader clinical application. Type of study/level of evidence: Therapeutic III.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.